Back to Search Start Over

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Authors :
Sauta, E
Robin, M
Bersanelli, M
Travaglino, E
Meggendorfer, M
Zhao, L
Caballero Berrocal, J
Sala, C
Maggioni, G
Bernardi, M
Di Grazia, C
Vago, L
Rivoli, G
Borin, L
D'Amico, S
Tentori, C
Ubezio, M
Campagna, A
Russo, A
Mannina, D
Lanino, L
Chiusolo, P
Giaccone, L
Voso, M
Riva, M
Oliva, E
Zampini, M
Riva, E
Nibourel, O
Bicchieri, M
Bolli, N
Rambaldi, A
Passamonti, F
Savevski, V
Santoro, A
Germing, U
Kordasti, S
Santini, V
Diez-Campelo, M
Sanz, G
Sole, F
Kern, W
Platzbecker, U
Ades, L
Fenaux, P
Haferlach, T
Castellani, G
Della Porta, M
Sauta, Elisabetta
Robin, Marie
Bersanelli, Matteo
Travaglino, Erica
Meggendorfer, Manja
Zhao, Lin-Pierre
Caballero Berrocal, Juan Carlos
Sala, Claudia
Maggioni, Giulia
Bernardi, Massimo
Di Grazia, Carmen
Vago, Luca
Rivoli, Giulia
Borin, Lorenza
D'Amico, Saverio
Tentori, Cristina Astrid
Ubezio, Marta
Campagna, Alessia
Russo, Antonio
Mannina, Daniele
Lanino, Luca
Chiusolo, Patrizia
Giaccone, Luisa
Voso, Maria Teresa
Riva, Marta
Oliva, Esther Natalie
Zampini, Matteo
Riva, Elena
Nibourel, Olivier
Bicchieri, Marilena
Bolli, Niccolo'
Rambaldi, Alessandro
Passamonti, Francesco
Savevski, Victor
Santoro, Armando
Germing, Ulrich
Kordasti, Shahram
Santini, Valeria
Diez-Campelo, Maria
Sanz, Guillermo
Sole, Francesc
Kern, Wolfgang
Platzbecker, Uwe
Ades, Lionel
Fenaux, Pierre
Haferlach, Torsten
Castellani, Gastone
Della Porta, Matteo Giovanni
Sauta, E
Robin, M
Bersanelli, M
Travaglino, E
Meggendorfer, M
Zhao, L
Caballero Berrocal, J
Sala, C
Maggioni, G
Bernardi, M
Di Grazia, C
Vago, L
Rivoli, G
Borin, L
D'Amico, S
Tentori, C
Ubezio, M
Campagna, A
Russo, A
Mannina, D
Lanino, L
Chiusolo, P
Giaccone, L
Voso, M
Riva, M
Oliva, E
Zampini, M
Riva, E
Nibourel, O
Bicchieri, M
Bolli, N
Rambaldi, A
Passamonti, F
Savevski, V
Santoro, A
Germing, U
Kordasti, S
Santini, V
Diez-Campelo, M
Sanz, G
Sole, F
Kern, W
Platzbecker, U
Ades, L
Fenaux, P
Haferlach, T
Castellani, G
Della Porta, M
Sauta, Elisabetta
Robin, Marie
Bersanelli, Matteo
Travaglino, Erica
Meggendorfer, Manja
Zhao, Lin-Pierre
Caballero Berrocal, Juan Carlos
Sala, Claudia
Maggioni, Giulia
Bernardi, Massimo
Di Grazia, Carmen
Vago, Luca
Rivoli, Giulia
Borin, Lorenza
D'Amico, Saverio
Tentori, Cristina Astrid
Ubezio, Marta
Campagna, Alessia
Russo, Antonio
Mannina, Daniele
Lanino, Luca
Chiusolo, Patrizia
Giaccone, Luisa
Voso, Maria Teresa
Riva, Marta
Oliva, Esther Natalie
Zampini, Matteo
Riva, Elena
Nibourel, Olivier
Bicchieri, Marilena
Bolli, Niccolo'
Rambaldi, Alessandro
Passamonti, Francesco
Savevski, Victor
Santoro, Armando
Germing, Ulrich
Kordasti, Shahram
Santini, Valeria
Diez-Campelo, Maria
Sanz, Guillermo
Sole, Francesc
Kern, Wolfgang
Platzbecker, Uwe
Ades, Lionel
Fenaux, Pierre
Haferlach, Torsten
Castellani, Gastone
Della Porta, Matteo Giovanni
Publication Year :
2023

Abstract

Purpose: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. Methods: A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed. Results: IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival, respectively). This was true even in those patients without detectable gene mutations. Compared with the IPSS-R based stratification, the IPSS-M risk group changed in 46% of patients (23.6% and 22.4% of subjects were upstaged and downstaged, respectively).In patients treated with hematopoietic stem cell transplantation (HSCT), IPSS-M significantly improved the prediction of the risk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance was 0.76 v 0.60 for overall survival and 0.89 v 0.70 for probability of relapse, respectively). In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probability of response; response duration and probability of survival were inversely related to IPSS-M risk.Finally, we tested the accuracy in predicting IPSS-M when molecular information was missed and we defined a minimum set of 15 relevant genes associated with high performance of the score. Conclusion: IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevan

Details

Database :
OAIster
Notes :
ELETTRONICO, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1383764780
Document Type :
Electronic Resource